Medifast, Inc. (MED) Income Statement

The year-over-year decline rates ranging from roughly -19 percent to -43 percent indicate a sustained demand contraction rather than a single cyclical dip. The most recent quarter's -19.4 percent rate is the smallest decline in the series, which may suggest deceleration of the downturn, but a single data point is insufficient to confirm a bottom. Investors should monitor whether sequential revenue stabilizes near current levels.

The stability of gross margin during a steep revenue decline suggests that pricing and product mix have largely insulated unit economics from volume pressure. However, the drift from the 75 percent range in 2024 toward the high 60s in 2026 may indicate emerging pricing pressure or unfavorable mix shifts. Whether this gradual erosion persists warrants further investigation.

SG&A expense has not contracted in proportion to revenue, so the fixed-cost base appears to be absorbing a growing share of a shrinking gross profit pool. This pattern indicates negative operating leverage, where each dollar of lost revenue erodes operating income by more than a dollar. Management's ability to right-size overhead will likely determine whether profitability can recover at lower revenue levels.